FibroGen reports Phase I/II data for pamrevlumab in pancreatic cancer

FibroGen Inc. (NASDAQ:FGEN) reported data from 37 evaluable treatment-naïve patients with locally advanced, unresectable

Read the full 145 word article

User Sign In